vs
Side-by-side financial comparison of COMSCORE, INC. (SCOR) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $93.5M, roughly 1.1× COMSCORE, INC.). COMSCORE, INC. runs the higher net margin — 3.2% vs -29.4%, a 32.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -1.5%). COMSCORE, INC. produced more free cash flow last quarter ($2.9M vs $-34.8M).
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
SCOR vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $93.5M | $103.7M |
| Net Profit | $3.0M | $-30.5M |
| Gross Margin | 41.0% | 52.0% |
| Operating Margin | 7.0% | -31.7% |
| Net Margin | 3.2% | -29.4% |
| Revenue YoY | -1.5% | 16.9% |
| Net Profit YoY | -3.7% | 3.4% |
| EPS (diluted) | $9.50 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.5M | $103.7M | ||
| Q3 25 | $88.9M | — | ||
| Q2 25 | $89.4M | — | ||
| Q1 25 | $85.7M | — | ||
| Q4 24 | $94.9M | — | ||
| Q3 24 | $88.5M | — | ||
| Q2 24 | $85.8M | — | ||
| Q1 24 | $86.8M | — |
| Q4 25 | $3.0M | $-30.5M | ||
| Q3 25 | $453.0K | — | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-60.6M | — | ||
| Q2 24 | $-1.7M | — | ||
| Q1 24 | $-1.1M | — |
| Q4 25 | 41.0% | 52.0% | ||
| Q3 25 | 40.6% | — | ||
| Q2 25 | 40.6% | — | ||
| Q1 25 | 39.6% | — | ||
| Q4 24 | 42.4% | — | ||
| Q3 24 | 41.2% | — | ||
| Q2 24 | 39.5% | — | ||
| Q1 24 | 42.3% | — |
| Q4 25 | 7.0% | -31.7% | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | -1.9% | — | ||
| Q1 25 | -2.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | -67.4% | — | ||
| Q2 24 | -2.2% | — | ||
| Q1 24 | -2.2% | — |
| Q4 25 | 3.2% | -29.4% | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | -10.6% | — | ||
| Q1 25 | -4.7% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -68.5% | — | ||
| Q2 24 | -2.0% | — | ||
| Q1 24 | -1.2% | — |
| Q4 25 | $9.50 | $-0.50 | ||
| Q3 25 | $-0.86 | — | ||
| Q2 25 | $-2.73 | — | ||
| Q1 25 | $-1.66 | — | ||
| Q4 24 | $-0.47 | — | ||
| Q3 24 | $-12.79 | — | ||
| Q2 24 | $-1.19 | — | ||
| Q1 24 | $-1.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $197.9M |
| Total DebtLower is stronger | $41.5M | — |
| Stockholders' EquityBook value | $111.4M | $456.1M |
| Total Assets | $407.7M | $638.1M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $197.9M | ||
| Q3 25 | $26.7M | — | ||
| Q2 25 | $26.0M | — | ||
| Q1 25 | $31.0M | — | ||
| Q4 24 | $29.9M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $14.7M | — | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $111.4M | $456.1M | ||
| Q3 25 | $-26.3M | — | ||
| Q2 25 | $-21.7M | — | ||
| Q1 25 | $-13.5M | — | ||
| Q4 24 | $-8.3M | — | ||
| Q3 24 | $-2.7M | — | ||
| Q2 24 | $45.8M | — | ||
| Q1 24 | $51.4M | — |
| Q4 25 | $407.7M | $638.1M | ||
| Q3 25 | $406.9M | — | ||
| Q2 25 | $415.9M | — | ||
| Q1 25 | $421.5M | — | ||
| Q4 24 | $430.2M | — | ||
| Q3 24 | $412.5M | — | ||
| Q2 24 | $474.1M | — | ||
| Q1 24 | $477.7M | — |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-24.8M |
| Free Cash FlowOCF − Capex | $2.9M | $-34.8M |
| FCF MarginFCF / Revenue | 3.1% | -33.5% |
| Capex IntensityCapex / Revenue | 0.3% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | $21.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-24.8M | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $932.0K | — | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $-10.0M | — | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $6.9M | — |
| Q4 25 | $2.9M | $-34.8M | ||
| Q3 25 | $9.4M | — | ||
| Q2 25 | $787.0K | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $6.6M | — |
| Q4 25 | 3.1% | -33.5% | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 10.1% | — | ||
| Q4 24 | -10.8% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 10.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 0.3% | 9.6% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.07× | — | ||
| Q3 25 | 20.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
